scholarly journals Risk factors for late-onset lower limb lymphedema after gynecological cancer treatment: A multi-institutional retrospective study

2020 ◽  
Vol 46 (7) ◽  
pp. 1334-1338 ◽  
Author(s):  
Masato Yoshihara ◽  
Ryoko Shimono ◽  
Satoko Tsuru ◽  
Kaoru Kitamura ◽  
Hiromi Sakuda ◽  
...  
Author(s):  
Sho Tano ◽  
Takehiko Takeda ◽  
Kaname Uno ◽  
Masato Yoshihara ◽  
Michinori Mayama ◽  
...  

BMC Cancer ◽  
2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Masato Yoshihara ◽  
Kaoru Kitamura ◽  
Satoko Tsuru ◽  
Ryoko Shimono ◽  
Hiromi Sakuda ◽  
...  

Abstract Background Lower limb lymphedema (LLL) is one of the most refractory and debilitating complications related to gynecological cancer treatment. We investigated factors associated with response to compression-based physical therapy (CPT) for secondary LLL after gynecologic cancer treatment. Methods We performed a multicenter retrospective study using the records of seven medical institutions from 2002 and 2014. Patients who developed LLL after gynecological cancer treatment were included. Limb volumes were calculated from the lengths of the limb circumferences at four points. All participants underwent compression-based physical therapy for LLL. Factors, including MLD, indicative of circumference reductions in LLL were determined. Results In total, 1,034 LLL met the required criteria of for the study. A multivariate linear regression analysis identified age; body mass index (BMI); endometrial cancer; radiotherapy; and initial limb circumference as significant independent prognostic factors related to improvement in LLL. In analysis of covariance for improvement in LLL adjusted by the initial limb circumference and stratified by BMI and radiotherapy, patients with BMI 28 kg/m2 or higher and receiving radiation rarely responded to CPT. Conclusions Improvements in the lower limb circumference correlated with clinical histories and physical characteristics, which may be used as independent prognostic factors for successful CPT for LLL after gynecological cancer treatment.


Author(s):  
Sho Tano ◽  
Yusuke Yamauchi ◽  
Kaname Uno ◽  
Takehiko Takeda ◽  
Masato Yoshihara ◽  
...  

2013 ◽  
Vol 4;16 (4;7) ◽  
pp. 345-352
Author(s):  
Hahck Soo Park

Background: Eighteen to 25% of patients after gynecological cancer treatment suffer from lower limb lymphedema (LLL) that decreases the quality of life of gynecological cancer survivors. Lumbar sympathetic ganglion block (LSGB) is widely used in practice for the evaluation and management of sympathetically mediated pain in the lower limbs. Several articles have suggested that sympathetic ganglion block could be an effective treatment for lymphedema. Objectives: To investigate the effect of LSGB on patients with secondary lymphedema related to the treatment of gynecologic cancer, who do not respond to a conservative treatment. Study Design: Prospective clinical study. Setting: A single academic medical center, outpatient setting. Methods: Eighteen patients with stage II lower limb lymphedema who did not response to the conservative treatment were recruited. The patients underwent fluoroscopy-guided LSGB 3 times at 2-week intervals. The circumference of the thigh and calf was measured in the upright position at the first visit and 2 weeks after each session of LSGB. The pain score of the lower limb was checked at the same time by a numeric rating scale (NRS) from 0 to 10. The patients were asked about their satisfaction with the procedure at the last follow-up visit. The Wilcoxon signed rank test was used for data analysis. Significance was accepted at a P-value less than 0.05/3. Results: The circumferences of affected thighs and calves decreased from 56.38 ± 4.77 and 35.33 ± 3.51cm to 54.42 ± 5.27 and 34.41 ± 3.35cm, respectively, in a significant manner after 3 consecutive LSGBs (P < 0.05/3). The maximal decrease after the third LSGB was 4 cm in the thigh and 2cm in the calf. The pain score also showed a significant decrease after 3 consecutive LSGBs from 2.17 to 1.28. The tightness and heaviness of the affected limb decreased after the first LSGB in 15 patients (83.3%) and after the second LSGB in 2 patients (11.1%). Five of 18 patients (27.8%) answered that the result of the LSGB met their expectations, 10 (55.6%) answered they would undergo the same treatment for the same outcome, 2 (11.1%) answered they did not improve as much as they had hoped, and they would not undergo the same treatment for the same outcome, and only one patient (5.6%) answered the LSGB showed no effect. Limitations: This study lacks a placebo control group and has only 18 patients. We did not evaluate the quality of life of the patients. Conclusion: We suggest that LSGB can be one of the treatment options for patients suffering from LLL after gynecologic cancer treatment. Our result could provide a basis for a randomized controlled trial in future investigations. The pain physicians can play an important role as one of the multidisciplinary team for a comprehensive treatment of LLL. Key words: Lumbar sympathetic ganglion block;gynecologic cancer;lymphedema


2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e24039-e24039
Author(s):  
Rosalind Guest ◽  
Noah Zanville ◽  
Lisellet Morin ◽  
Muni Rubens ◽  
M. Beatriz Currier

e24039 Background: Improvements in breast cancer screening and treatment have improved survival for many women in the U.S. However, side-effects associated with cancer treatment remain a serious issue for survivors. It is estimated that up to half or more of female breast cancer survivors (BSC) report unwanted changes in sexual function following cancer treatment. Studies have also suggested that both younger BCS and Hispanic women may be at higher risk for developing sexual dysfunction following treatment. However, women of Hispanic origin remain highly underrepresented in research on sexual dysfunction, despite being one of the fastest growing racial/ethnic populations in the U.S. The purpose of this study was to compare the prevalence and risk factors for sexual dysfunction between Hispanic and non-Hispanic BCS during the first-three years post-cancer treatment. Methods: Data for this single-center, non-randomized, retrospective study came from a database of self-reported symptom data collected as part of routine clinical practice in our institution’s Survivorship Clinic. Results: Over a 2.8-year period between Apr. 2017 and Dec. 2019, a total 815 female BCS were evaluated for sexual dysfunction. Nearly two-thirds (63.0%) of BCS identified as Hispanic, and 37.0% (n = 302) of BCS identified as non-Hispanic. Mean age of the sample was 58.4 ± 11.7 (range: 24.2–91.8). Results found that approximately a quarter (25.8%) of BCS reported “vaginal dryness, discharge, or pain with intercourse” at their initial survivorship visit. Rates of sexual dysfunction were nearly identical between Hispanic and Non-Hispanic BCS (25.7% vs. 25.8%; p = 0.975). Consistent with previous studies, BCS who reported sexual dysfunction tended to be younger, on average (53.7±10.5 years vs. 60.0 ±11.6 years; p = 0.002) and more likely to have been diagnosed with Stage 2 or 3 cancer (p = 0.038) than BCS not reporting sexual dysfunction. Multivariate logistic regression models using age, race, stage of cancer, chemotherapy, radiation type, and hormone therapy as predictors confirmed this association between younger age and likelihood of sexual dysfunction, showing that for every one-year younger BCS were at their initial survivorship visit, the odds of reporting sexual dysfunction at the initial survivorship visit increased by approximately 6.5% (OR: 0.943, 95% CI: 0.927-0.96; p < .0001). Conclusions: Results suggest that signs/symptoms such as vaginal dryness, discharge, or pain with intercourse are common for both Hispanic and non-Hispanic BCS following treatment, affecting as many as one in four BCS. Results also show that symptoms are prevalent among younger BCS. Together, results underscore the need for clinicians to be prepared to assess and manage sexual dysfunction, especially in younger BCS.


2017 ◽  
Vol 15 (2) ◽  
pp. 166-171 ◽  
Author(s):  
Katarzyna Ochalek ◽  
Katarzyna Pacyga ◽  
Marta Curyło ◽  
Aleksandra Frydrych–Szymonik ◽  
Zbigniew Szygula

Author(s):  
Noori Khalid ◽  
Adarsh Dharmarajan ◽  
Satheeshan B. ◽  
Biji M. S. ◽  
Abina S. S. ◽  
...  

Background: The development of postoperative lower limb lymphedema (LLL) is a disabling, yet usually overlooked sequele of most gynecological cancer treatment. It can lead to significant functional problems that negatively affect gynecological cancer survivors’ daily living, work, emotional state, and overall quality of life. The objective of this study is to calculate the incidence of lower limb lymphedema in patients undergoing surgery for gynecological cancer and to evaluate the risk factors for its development.Methods: Women with newly diagnosed carcinoma ovary, carcinoma endometrium and carcinoma cervix, who underwent surgery at a tertiary cancer centre from September 2016 were included in the study. The circumference of both lower limbs was measured at prefixed sites. The limb volume was calculated using the formula C2/pi. A baseline value was taken prior to surgery. The patients were followed up every 3 months and the limb volume were calculated at each visit. An increase in limb volume by >10% was defined as lymphedema.Results: The incidence of lymphedema after 1 year follow up was 43.5%. There was no significant association between known risk factors such as extent of lymphadenectomy (p value 0.633) number of pelvic or para aortic lymph nodes removed (p value 0.69 and 0.44 respectively) and type of adjuvant therapy (p value 0.455).Conclusions: The incidence of LLL according to the present study was 43.5%. There was no statistically significant association between development of LLL and risk factors like site and number of lymph nodes removed and type of adjuvant therapy.


Author(s):  
Pramod P. Singhavi

Introduction: India has the highest incidence of clinical sepsis i.e.17,000/ 1,00,000 live births. In Neonatal sepsis septicaemia, pneumonia, meningitis, osteomyelitis, arthritis and urinary tract infections can be included. Mortality in the neonatal period each year account for 41% (3.6 million) of all deaths in children under 5 years and most of these deaths occur in low income countries and about one million of these deaths are due to infectious causes including neonatal sepsis, meningitis, and pneumonia. In early onset neonatal sepsis (EOS) Clinical features are non-specific and are inefficient for identifying neonates with early-onset sepsis. Culture results take up to 48 hours and may give false-positive or low-yield results because of the antenatal antibiotic exposure. Reviews of risk factors has been used globally to guide the development of management guidelines for neonatal sepsis, and it is similarly recommended that such evidence be used to inform guideline development for management of neonatal sepsis. Material and Methods: This study was carried out using institution based cross section study . The total number neonates admitted in the hospital in given study period was 644, of which 234 were diagnosed for neonatal sepsis by the treating pediatrician based on the signs and symptoms during admission. The data was collected: Sociodemographic characteristics; maternal information; and neonatal information for neonatal sepsis like neonatal age on admission, sex, gestational age, birth weight, crying immediately at birth, and resuscitation at birth. Results: Out of 644 neonates admitted 234 (36.34%) were diagnosed for neonatal sepsis by the paediatrician based on the signs and symptoms during admission. Of the 234 neonates, 189 (80.77%) infants were in the age range of 0 to 7 days (Early onset sepsis) while 45 (19.23%) were aged between 8 and 28 days (Late onset sepsis). Male to female ratio in our study was 53.8% and 46% respectively. Out of total 126 male neonates 91(72.2%) were having early onset sepsis while 35 (27.8%) were late onset type. Out of total 108 female neonates 89(82.4%) were having early onset sepsis while 19 (17.6%) were late onset type. Maternal risk factors were identified in 103(57.2%) of early onset sepsis cases while in late onset sepsis cases were 11(20.4%). Foul smelling liquor in early onset sepsis and in late onset sepsis was 10(5.56%) and 2 (3.70%) respectively. In early onset sepsis cases maternal UTI, Meconium stained amniotic fluid, Multipara and Premature rupture of membrane was seen in 21(11.67%), 19 (10.56%), 20(11.11%) and 33 (18.33%) cases respectively. In late onset sepsis cases maternal UTI, Meconium stained amniotic fluid, Multipara and Premature rupture of membrane was seen in 2 (3.70%), 1(1.85%), 3 (5.56%) and 3 (5.56%) cases respectively. Conclusion: Maternal risk identification may help in the early identification and empirical antibiotic treatment in neonatal sepsis and thus mortality and morbidity can be reduced.


Sign in / Sign up

Export Citation Format

Share Document